The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.

ABSTRACT:

Background

The mechanisms underlying disease pathogenesis in chronic spontaneous urticaria (CSU) and improvement with omalizumab are incompletely understood.

Objectives

This study sought to examine whether the rate of clinical remission is concordant with baseline basophil features or the rate of change of IgE-dependent functions of basophils and/or plasmacytoid dendritic cells during omalizumab therapy.

Methods

Adults (n = 18) with refractory CSU were treated with omalizumab 300 mg monthly for 90 days. Subjects recorded daily urticaria activity scores, and clinical assessments with blood sampling occurred at baseline and on days 1, 3, 6, 10, 20, 30, 60, and 90 following omalizumab. At baseline, subjects were categorized by basophil functional phenotypes, determined b

SUBMITTER: Johal KJ 

PROVIDER: S-EPMC8223444 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature